Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 5/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713046 | 0.89 | MAPT (0.59) | ADRA1DADRA1AADRA1BHTR1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3708818 | 0.88 | MAPT (0.58) | HTR1AALDH1A1 | |
| SCHEMBL2768032 | 0.86 | ADRA1D (0.61) | ADRA1DADRA1AADRA1BHTR1ASIGMAR1 | |
| SCHEMBL2769508 | 0.84 | ADRA1D (0.58) | ADRA1DADRA1AADRA1BHTR1ASIGMAR1 | |
| SCHEMBL2765952 | 0.82 | MEN1 (0.61) | ADRA1DADRA1AADRA1BHTR1AMEN1 | |
| SCHEMBL13150788 | 0.80 | SIGMAR1 (0.88) | SIGMAR1 | |
| SCHEMBL2766150 | 0.80 | SIGMAR1 (0.72) | ADRA1DADRA1AADRA1BHTR1ASIGMAR1 | |
| SCHEMBL14922712 | 0.77 | HTR3E (0.69) | HTR1AALDH1A1HTR3EHTR3BHTR3A | |
| SCHEMBL29342067 | 0.77 | HTR3E (0.53) | ADRA1DADRA1AADRA1BHTR1AHTR3E | |
| SCHEMBL5442134 | 0.77 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | ADRA1D 2006/4885ADRA1A 2425/4885ADRA1B 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.